Candel Therapeutics Inc (NASDAQ: CADL) is a clinical-stage biopharmaceutical company that develops oncolytic viral immunotherapy candidates for cancer treatment. The company has not generated product revenue from approved therapeutics and funds operations through equity offerings, at-the-market stock sales, term loan proceeds, and partnership arrangements. One licensing agreement, the Ventagen Agreement, provides for milestone payments and supply revenue: Ventagen agreed to pay $1,000,000 for research and development (received in 2014 and 2015) and a fixed future milestone payment of $2,500,000 upon achieving a specified sales threshold for a licensed product, plus clinical and commercial supply purchases at cost plus a specified markup. Candel is a pre-commercial company with no disclosed product approvals as of the 10-K filed 2026-03-12, relying on external financing to advance candidates through clinical trials toward potential regulatory approval.

Revenue model

Pre-commercial stage. Revenue sources disclosed in the filing include: a $1,000,000 research and development payment from Ventagen (received 2014-2015), a contingent $2,500,000 milestone payment from Ventagen tied to a specified sales threshold, supply revenue from Ventagen at cost plus a specified wholesale price markup, proceeds from at-the-market common stock offerings, proceeds from registered direct offerings and public offerings, term loan proceeds, and stock option exercises. No product sales revenue from approved therapeutics is disclosed.

Products and services

Oncolytic viral immunotherapy product candidates in clinical development. One licensed product covered under the Ventagen Agreement, for which Candel manufactures clinical and commercial supply. Specific candidate names and pipeline stage details are not supported by the provided filing excerpts.

Customers and end markets

Ventagen is identified as a licensing and supply partner. End markets are oncology and cancer immunotherapy. Specific customer counts, hospital relationships, or payer mix are not disclosed in the provided excerpts.

Value-chain role

Drug developer and manufacturer of clinical and commercial supply for licensed products. Candel conducts or sponsors clinical trials, handles regulatory affairs, and manufactures supply for at least one licensee (Ventagen). The company expects to contract with third-party CROs and other contractors for development activities.

Geographic exposure

U.S.-based operations. The Ventagen Agreement references a country-by-country royalty term structure, indicating potential international licensing scope, but specific geographic revenue breakdown is not disclosed in the provided excerpts.

Source: SEC 10-K, filed 2026-03-12

Industry: Biological Products, (No Diagnostic Substances) Peers: BIORA THERAPEUTICS, INC. CytomX Therapeutics Inc Decibel Therapeutics, Inc. INFINITY PHARMACEUTICALS, INC. Puma Biotechnology Inc Insight Molecular Diagnostics Inc Tourmaline Bio, Inc. vTv Therapeutics Inc